Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis

Mirosława Püsküllüoğlu; Agnieszka Rudzińska; Renata Pacholczak-Madej

doi:10.1016/j.bbcan.2023.188991

Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis

Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):188991. doi: 10.1016/j.bbcan.2023.188991. Epub 2023 Sep 26.

Authors

Mirosława Püsküllüoğlu¹, Agnieszka Rudzińska², Renata Pacholczak-Madej³

Affiliations

¹ Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Garncarska Street 11, 31-115 Krakow, Poland. Electronic address: miroslawa.puskulluoglu@krakow.nio.gov.pl.
² Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Garncarska Street 11, 31-115 Krakow, Poland.
³ Department of Anatomy, Jagiellonian University, Medical College, Kopernika Street 12, 31-034 Krakow, Poland; Department of Chemotherapy, The District Hospital, 22 Szpitalna Street, 34-200 Sucha Beskidzka, Poland.

PMID: 37758021
DOI: 10.1016/j.bbcan.2023.188991

Abstract

Antibody drug conjugates (ADCs) comprise a rapidly growing class of targeted drugs that selectively deliver a cytotoxic agent to cancer cells, reducing the side effects associated with conventional chemotherapy. Breast cancer (BC) is a heterogeneous entity. The need for effective therapies for HER-2 negative BCs with poor prognosis, such as triple-negative or endocrine-resistant BC, remains unmet due to the lack of potential targets for treatments. These BC subtypes are not candidates for hormonal or anti-HER-2 agents. However, ongoing clinical trials exploring the use of ADCs with a wide range of targets have shown potential for this treatment modality. In this review, we present the current state of knowledge regarding the role of ADC and speculate on novel approaches including ADC combination therapies, new molecular targets, and the role of other subclasses of ADCs (bicycle drug conjugates, bispecific ADCs, immune modulating ADCs) in this clinical scenario.

Keywords: Antibody drug conjugates; Clinical trials; HER-2 negative breast cancer; Hormonal- resistance; Targeted cancer therapy; Triple negative breast cancer.

Publication types

Review

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Drug Delivery Systems
Humans
Immunoconjugates* / pharmacology
Immunoconjugates* / therapeutic use
Molecular Targeted Therapy
Triple Negative Breast Neoplasms* / drug therapy

Substances

Immunoconjugates
Antineoplastic Agents